Mr. Macosko will be the Company's first US-based Board member
MELBOURNE, Australia, July 28, 2015 (GLOBE NEWSWIRE) -- Gordagen Pharmaceuticals, a private biopharmaceutical and nutraceutical company developing tocotrienols, today announced the appointment of Gregory Macosko to its board of directors, effective August 1, 2015. With this addition its Board now consists of five directors, of which, three directors are non-executive and independent.
Mr. Fred Nadjarian, the Chairman of Gordagen Pharmaceuticals, commented, "We are excited to have someone of Greg's calibre join our Board of Directors. He has had a long, established career in the financial industry and experience serving as a board member for companies in the biotechnology and sports nutrition space. His expertise in the US financial markets will be a tremendous asset as we begin commercialization and work to position the Company for long-term growth. We look forward to working with Greg and the contribution he will bring to our Board."
Mr. Macosko is currently a member of the Board of Directors of Montrose Advisors and also a business advisor to the Board of Directors of Bioxiness Pharmaceuticals, a California-based pre-clinical stage company focused on anti-infective pharmaceuticals. Previously, he served as a member of the Board of Directors and Chairman of the Audit Committee for MusclePharm, a public company based in Colorado focused on sports nutrition. In September of 2013, Mr. Macosko retired as a Partner from Lord Abbett & Co., a privately held investment management firm, where he served as a Portfolio Manager of Lord Abbett's Small Cap Value Fund and a founding member of the company's Proxy Committee. Prior to that, he was a senior research analyst at New York-based Royce & Associates where he researched and invested in small and micro-cap public companies across numerous industries, including biotechnology and pharmaceutical.
Mr. Macosko stated, "Joining the Board of Directors at Gordagen is a great opportunity to be part of a Company with an exciting and compelling story. With tocotrienol-based therapeutic agents that have demonstrated safety and improved delivery when compared to the currently marketed products, and target markets that include both pharmaceuticals and nutraceuticals, there is significant growth potential for the Company and its product portfolio. I'm excited to be joining such a highly regarded and experienced team and look forward to helping the Company achieve its long-term goals."
Mr. Macosko is a Phi Beta Kappa graduate of Albion College, a Fulbright Scholar in Germany, and holds an MBA from Columbia University.
| Investor and Media Inquiries: | |
| Paris Brooke – Australia and Asia | Ph: +61 (0) 407 715 574 |
| David Burke, The Ruth Group – Americas, Europe | Ph: +1 646 536-7009 |
About Gordagen Pharmaceuticals Pty Ltd
Gordagen Pharmaceuticals is a privately-held Australian company developing and commercialising evidence-based prescription medicines and nutraceuticals based on natural tocotrienols, found in vitamin E. The Company has developed a novel approach to delivering highly potent tocotrienols to target tissues using its proprietary and patented MELT3 delivery technology. The Company is focusing on tocotrienols with wide therapeutic potential, for the treatment of heart health, muscle soreness and exercise endurance and a range of indications with unmet medical needs (ie. Hyperlipidemia, hypertension and diabetes) www.gordagen.com.